Oxford Science Enterprises

Oxford Science Enterprises participated in Fractile's $220m Series B on 20 May 2026, taking a co-investor position alongside NATO Innovation Fund and In-Q-Tel . Oxford Science Enterprises is an existing stakeholder in Fractile from earlier funding rounds; its Series B participation maintains its position as Fractile grows into the $1bn valuation range. The fund's presence also places it in the same cap-table nexus as the Lansdowne Partners university spinout fund, which targets Oxford IP in semiconductors and quantum, creating overlapping institutional claims on Oxford's deeptech output .

Oxford Science Enterprises (OSE) was founded in 2015 with a £320m initial commitment from the University of Oxford and a consortium of institutional LPs, including Sequoia Capital and Woodford Investment Management (since exited). It has since raised successive funds with growing commercial LP participation, now managing over £1bn. OSE holds co-investment rights on Oxford University spinouts, giving it first-look access to technology commercialised through the university's technology transfer office. Its portfolio includes Oxford Nanopore Technologies (genomics, now FTSE-listed), Exscientia (AI drug discovery, Nasdaq) and multiple Quantum computing, materials Science, and AI hardware companies in formation. OSE operates a permanent capital model, reinvesting returns to maintain position across Oxford's deeptech pipeline.

OSE's participation in the Fractile round anchors the deal in the Oxford university IP nexus at the same moment that Lansdowne Partners is launching a competing fund explicitly targeting Oxford spinout IP. The cap-table density this creates, with OSE, Lansdowne's fund-of-funds, NATO-IF, and In-Q-Tel all potentially holding positions in the same generation of Oxford deeptech companies, raises structural questions about governance complexity at Series C, when those investors' mandates and exit preferences may diverge sharply.